Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...